4D Molecular Therapeutics (FDMT) Receivables (2019 - 2022)

4D Molecular Therapeutics (FDMT) has 4 years of Receivables data on file, last reported at $700000.0 in Q4 2022.

• Receivables for Q4 2022 came in at $700000.0, down 6.29% year-over-year; the trailing twelve-month figure through Dec 2022 was $700000.0 (down 6.29% YoY), and the FY2022 annual result was $700000.0, down 6.29% from the prior year.
• Receivables eased to $700000.0 in Q4 2022 per FDMT's latest filing, from $747000.0 in the prior quarter.
• Over five years, Receivables peaked at $1.5 million in Q4 2020 and troughed at $700000.0 in Q4 2022.
• A 4-year average of $940400.0 and a median of $791000.0 in 2021 frame the typical range for Receivables.
• The sharpest annual moves came in 2020 and 2021: Receivables soared 51.94% in 2020, then slumped 49.73% in 2021.
• A 4-year view of Receivables shows it stood at $978000.0 in 2019, then soared by 51.94% to $1.5 million in 2020, then plunged by 49.73% to $747000.0 in 2021, then retreated by 6.29% to $700000.0 in 2022.
• Business Quant data shows FDMT's Receivables at $700000.0 in Q4 2022, $747000.0 in Q4 2021, and $791000.0 in Q3 2021.